Objectives: Deep learning algorithms have shown potential in streamlining difficult clinical decisions. In the present study, we report the diagnostic profile of a deep learning model in differentiating malignant and benign lymph nodes in patients with papillary thyroid cancer.
Methods: An in-house deep learning-based model called "ClymphNet" was developed and tested using two datasets containing ultrasound images of 195 malignant and 178 benign lymph nodes. An expert radiologist also viewed these ultrasound images and extracted qualitative imaging features used in routine clinical practice. These signs were used to train three different machine learning algorithms. Then the deep learning model was compared with the machine learning models on internal and external validation datasets containing 22 and 82 malignant and 20 and 76 benign lymph nodes, respectively.
Results: Among the three machine learning algorithms, the support vector machine model (SVM) outperformed the best, reaching a sensitivity of 91.35%, specificity of 88.54%, accuracy of 90.00%, and an area under the curve (AUC) of 0.925 in all cohorts. The ClymphNet performed better than the SVM protocol in internal and external validation, achieving a sensitivity of 93.27%, specificity of 92.71%, and an accuracy of 93.00%, and an AUC of 0.948 in all cohorts.
Conclusion: A deep learning model trained with ultrasound images outperformed three conventional machine learning algorithms fed with qualitative imaging features interpreted by radiologists. Our study provides evidence regarding the utility of ClymphNet in the early and accurate differentiation of benign and malignant lymphadenopathy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jum.16131 | DOI Listing |
Surgery
January 2025
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Background: We investigated the rational extent of regional lymphadenectomy and evaluated the prognostic impact of number-based regional nodal classification in patients with distal cholangiocarcinoma.
Methods: This study included 191 patients with distal cholangiocarcinoma who underwent pancreaticoduodenectomy. The nos.
Neurol Neuroimmunol Neuroinflamm
March 2025
MeLis Institute, SynatAc Team, Inserm U1314/ UMR CNRS5284, France.
Background And Objectives: Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression of the Yo-onconeural antigens. They are infiltrated by an unusual proportion of B cells. We investigated whether these features were also observed in patients with PNS and anti-Ri antibodies (Ri-PNS).
View Article and Find Full Text PDFSci Immunol
January 2025
Koch Institute at MIT, Cambridge, MA 02139, USA.
Immune responses against cancer are dominated by T cell exhaustion and dysfunction. Recent advances have underscored the critical role of early priming interactions in establishing T cell fates. In this review, we explore the importance of dendritic cell (DC) signals in specifying CD8 T cell fates in cancer, drawing on insights from acute and chronic viral infection models.
View Article and Find Full Text PDFSTAR Protoc
January 2025
Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden; Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden. Electronic address:
Here, we present a protocol for guiding tissue preparation and flow cytometric analysis in subcutaneous murine tumor models and secondary lymphoid organs. We describe steps for dissociating tumors, spleens, and lymph nodes to obtain single-cell suspensions. We then detail procedures for immune cell staining and analysis and gating strategies including the use of fluorescence-minus-one controls (FMOs).
View Article and Find Full Text PDFAnn Surg Treat Res
January 2025
Department of Surgery, Hanyang University Guri Hospital, Guri, Korea.
Purpose: Patients with stage I colorectal cancer (CRC) rarely experience recurrence after curative resection. Therefore, the risk factors for stage I CRC recurrence are yet to be established. We aimed to identify risk factors for stage I CRC recurrence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!